Our Mission...
is to improve the quality of health service delivery and reduce the burden of disease and disability in the United States and elsewhere by carrying out broadly based research and education activities involving the translation of innovative medical research into practice

PUBLICATIONS

2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004

 

2015

 

 

Grosse SD, Palomaki GE, Mvundura M, Hampel H: The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates. Genet Med, 17:510-511, 2015.

Haddow JE, Neveux LM, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME: An inverse relationship between weight and free thyroxine during early gestation among women treated for hypothyroidism. Thyroid, 25:949-953, 2015.

Kloza EM, Haddow PK, Halliday JV, O'Brien BM, Lambert-Messerlian GM, Palomaki GE: Evaluation of patient education materials: the example of circulating cell free DNA testing for aneuploidy. J Genet Couns, 24:259-266, 2015.

Lyon E, Cockerill FR 3rd, Bale SJ, Beadling D, Bry L, Hagenkord J, Kulkarni S, Press R, Palomaki GE: Next generation sequencing in clinical diagnostics: experiences of early adopters. Clin Chem, 61:41-49, 2015.

Lyon E, Schrijver I, Weck KE, Ferreira-Gonzalez A, Richards CS, Palomaki GE: Molecular genetic testing for cystic fibrosis: laboratory performance on the College of American Pathologists external proficiency surveys. Genet Med, 17:216-225, 2015.

Palomaki GE, Haddow JE, Haddow H, Salahuddin S, Geahchan C, Cerdeira AS, Verlohren S, Perschel FH, Horowitz G, Thadhani R, Karumanchi SA, Rana S: Modeling risk for adverse outcomes in women with suspected preterm preeclampsia using angiogenic factor measurements. Prenancy Hypertens, 5:12, 2015 (Abstract).

Palomaki GE, Haddow JE, Haddow H, Salahuddin S, Geahchan C, Cerdeira AS, Verlohren S, Perschel FH, Horowitz G, Thadhani R, Karumanchi SA, Rana S: Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenat Diagn, 35:386-393, 2015.

Palomaki GE, Ashwood ER, Weck KE: A flawed challenge but valid recommendation: a response to Takoudes and Hamar. Ultrasound Obstet Gynecol, 45:117, 2015.

Palomaki GE, Kloza EM, Lambert-Messerlian GM, van den Boom D, Ehrich M, Deciu C, Bombard AT, Haddow JE: Circulating cell free DNA testing: are some test failures informative? Prenat Diagn, 35:289-293, 2015.

Palomaki GE: Is it time for BRCA1/2 mutation screening in the general adult population?: Impact of population characteristics. Genet Med, 17:24-26, 2015.

Palomaki GE, Ashwood AR, Best RG, Lambert-Messerlian G, Knight GJ: Is maternal plasma DNA testing impacting serum-based screening for aneuploidy in the United States. Genet Med, 17:897-900, 2015.

Palomaki GE, Eklund EE, Neveux LM, Lambert-Messerlian GM: Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: High detection with low rates of invasive procedures. Prenat Diagn, 35:789-796, 2015.

Palomaki GE: Screening for breast cancer by molecular testing for three founder mutations in the BRCA1 and BRCA2 genes among women of Ashkenazi Jewish heritage. J Med Screen, 22:109-111, 2015.

Tafe LJ, Datto MB, Palomaki GE, Lacbawan FL; CAP/ACMG Biochemical and Molecular Genetics Resource Committee: Molecular testing for the BRCA1 and BRCA2 Ashkenzai Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys. Genet Med, 17:58-62, 2015.